PhaseBio gets FDA nod to begin Covid-19 trial with VIP receptor agonist PB1046

PhaseBio Pharmaceuticals has secured approval from the US Food and Drug Administration (FDA) to begin a VANGARD pivotal clinical to assess PB1046 as a treatment for hospitalised Covid-19 patients.